Kornimate/medical-research-clean huggingface dataset:
study comparing osseospeed™ implants of two different lengths in the upper and lower posterior jaw

Conditions: Jaw, Edentulous, Partially

Summary: the purpose of this study is to see if osseospeed™ implant 6 mm long is effective for rehabilitation of edentulism and if so, how it compares with osseospeed™ implant 11 mm long. the primary hypothesis is that the alteration in bone level is equal in patients randomized to 6 mm as to patients randomized to 11 mm implants.


Eligibility criteria:
inclusion criteria: * provision of informed consent * aged 20-70 years at enrolment * history of edentulism in the study area of at least four months * neighboring tooth/teeth to the planned bridge must have natural root(s) * presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in contact with the planned bridge. * deemed by the investigator to have a bone height of at least 11 mm and a bone width of minimum 6 mm * deemed by the investigator as likely to present an initially stable implant situation exclusion criteria: * unlikely to be able to comply with study procedures, as judged by the investigator * earlier graft procedures in the study area * uncontrolled pathologic processes in the oral cavity * known or suspected current malignancy * history of radiation therapy in the head and neck region * history of chemotherapy within 5 years prior to surgery * systemic or local disease or condition that could compromise post-operative healing and/or osseointegration * uncontrolled diabetes mellitus * corticosteroids or any other medication that could influence post-operative healing and/or osseointegration * smoking more than 10 cigarettes/day * present alcohol and/or drug abuse * involvement in the planning and conduct of the study (applies to both astra tech staff and staff at the study site) * previous enrolment in the present study. * severe non-compliance to protocol as judged by the investigator and/or astra tech * simultaneous participation in another clinical study, or participation in a clinical study during the last 6 months
profile of plasma growth factors before and after head and neck oncological or non-oncological surgery

Conditions: Head and Neck Squamous Cell Carcinoma; Growth Factor; Surgery

Summary: the obvious hypothesis is that the application of peri-operative targeted biological agents may counteract the tumor growth effect of these circulating factors and improve patient outcome


Eligibility criteria:
inclusion criteria: * age 18 years and over _ histological proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharinx or larynx * patients selected for a primary surgical treatment * no distant metastases * no active second malignancy during the last 5 years except non melanoma skin cancer or carcinoma in situ of the cervix * no prior or concurrent evidence of uncontrolled severe pathology precluding administration of surgery * life expectancy of more than 3 months * not pregnant or nursing; fertile patients both male and female, must use effective contraception * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial * signed informed consent * performance status ecog 0-1 exclusion criteria: * nasopharynx cancer * past or current malignancy other than hnscc * performance ecog status more than 2 * concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not indicated in the study protocol * use of any investigational agents within 4 weeks prior to entry * previous exposure to egfr targeting therapy * known grade hypersensitivity to cetuximab * legal incapacity or limited legal capacity or medical or psychological condition which in the opiniion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
handheld echocardiography in clinical practice

Conditions: Cardiovascular Disease

Summary: transthoracic echocardiography (tte) represents an established and fundamental tool for the evaluation of patients with known or suspected cardiovascular disease. recently, manufacturers have developed handheld echocardiograms small enough to fit in the pocket of a physician's lab coat. studies assessing these handheld devices have several limitations. while they have generally evaluated the handheld devices favorably, previous studies has not consistently studied handheld devices under the best possible clinical conditions and have not necessarily highlighted the devices' limitations. in this proposal, we seek to analyze the applicability of handheld echocardiograms to standard clinical practice. the investigators plan to use trained sonographers to perform handheld examinations on patients referred for tte without established cardiovascular disease. the handheld images will be interpreted by experienced, consultant-level echocardiographers. the investigators then plan to compare findings from the handheld echocardiogram to the patient's standard clinical tte.


Eligibility criteria:
inclusion criteria * adult patients referred for a resting transthoracic echocardiogram. exclusion criteria * referral for quantitative assessment of valvular heart disease * referral for strain imaging * referral for measurement of left atrial mechanical function or cardiac resynchronization studies * known diagnosis of congenital heart disease, restrictive cardiomyopathy, constrictive pericardial disease, or pulmonary hypertension * patients who have received left ventricular assist devices or those who have undergone cardiac transplants

Keywords: handheld echocardiography v-scan handheld ultrasound portable ultrasound
study of debio 1450 for bacterial skin infections

Conditions: Bacterial Infections

Summary: the primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal absssi.


Eligibility criteria:
inclusion criteria: * has clinically documented infection of the skin or skin structure suspected or documented to be caused by a staphylococcal pathogen * meets other protocol-specified criteria for qualification and contraception * is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications * voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures exclusion criteria: * has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters * has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or well-being of the participant or study staff; 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3. the analysis of results
a study of evorpacept (alx148) in patients with advanced solid tumors and lymphoma (aspen-01)

Conditions: Metastatic Cancer; Solid Tumor; Advanced Cancer; NonHodgkin Lymphoma

Summary: a phase 1, dose escalation study of evorpacept (alx148) in patients with advanced solid tumors and lymphoma

this phase 1 clinical study (at148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, pk, and pd study of evorpacept (alx148). the phase 1 protocol will have 2 parts: a single agent dose escalation phase (part 1) and a combination therapy phase (part 2). part 2 will include an initial dose escalation portion followed by a dose expansion portion. approximately 184 adult patients are expected to be enrolled in the study.

Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory non-hodgkin lymphoma for whom no standard therapy is available.. * adequate bone marrow function. * adequate renal \& liver function. * adequate performance status exclusion criteria: * patients with known symptomatic cns metastases or lepotomeningeal disease requiring steroids. * previous high-dose chemotherapy requiring allogenic stem cell rescue. * prior treatment with a cd47 or signal regulatory protein (sirp) alpha targeting agent.

Keywords: neoplasms cd47 sirpα alx148 evorpacept
pedagogues promoting positive parenting in a home-visiting program in at-risk families: a rct of vipp-sd

Conditions: Behavior Problems in Early Childhood

Summary: supportive parenting is a strong predictor of positive outcomes for children, and harsh parenting is a risk factor for child development, especially for the child developing externalizing problems (overactive, oppositional, and aggressive behavior). externalizing problems in preschoolers are predictive of a variety of problems in later childhood. thus, parents are key targets for change in preventive programs with children at risk for developing externalizing problems. more than 95% of 2-6 year old danish children spend an average of 7.5 hours, 5 days a week in a daycare setting, thus pedagogues are key frontline staff in the promotion of parental abilities and early childhood mental health. however, a recent danish study shows that pedagogues experience a need for systematic skills and methods for intervening in families with a child at risk. attachment-based programs enhancing parental sensitivity and parental sensitive discipline show promising results. this efficacy study examines the video-feedback intervention to promote positive parenting and sensitive discipline (vipp-sd)delivered by 22 vipp-sd trained pedagogues at home-visits to 120 families with a child (1-6 years) identified to be at risk. pedagogues are supervised by four vipp municipality psychologists, thus promoting the cross-disciplinary collaboration. the results will point to future identification of families that may (and may not) profit from a pedagogue delivered vipp-sd intervention, as well as to revise the intervention in order to maximizing its effect, i.e. point to changes to tailor intervention to the particular needs of different families in a danish context.


Eligibility criteria:
inclusion criteria: * child 2-6 year old * parent must be more than 18 years old * parent must speak and understand danish * family must live in the municipalities of frederiksberg or roskilde - and having no intentions of moving out of the municipality before after the intervention has ended * parent can attend other treatment initiatives * child must attend a daycare center in one of the two municipalities * child must be at risk of developing externalizing behavior, i.e. showing signs of overactive, oppositional, and aggressive behavior. exclusion criteria * sexual or physical abuse by parent * parental drug or alcohol abuse * child diagnosis of autism * child is not considered at risk of developing externalizing behavior problems, but may have other problems, such as delayed language or motordevelopment etc

Keywords: selected early intervention parental sensitivity and sensitive discipline child externalizing behavior pedagogues
double rewire versus double kissing crush stenting technique in left main bifurcation lesions

Conditions: Coronary Artery Disease

Summary: the dr vs dk trial is designed to elucidate the benefits of double rewire crush technique (dr-crush) over double kissing crush (dk-crush) technique in patients with unprotected left main bifurcation lesions (ulmb).

dr vs dk is a multicentre, randomized, prospective, non-inferiority clinical trial designed to evaluate the efficacy and safety of dr crush over dk crush for patients with ulmb. more than 12 tertiary centres from spain will participate including patients. subjects with medina 1,1,1 ulmb will be randomized in a 1:1 fashion to dr or dk crush. in order to avoid bias, the sirolimus coronary stent will be used in all patients (ultimastertm tanseitm). the use of intracoronary imaging techniques are recommended. the primary endpoint is target lesion failure (tlf) including target vessel myocardial infarction, cardiac death and tlr. other endpoints address individual event of primary end-point, and target vessel revascularization. the safety objective is the st. recruitment began in january 2022 and will be completed in january 2024; 180 patients will be randomized.

Eligibility criteria:
inclusion criteria: * patients between 18-90 years of age. * patients who gave written informed consent for participation in the trial. * lesions are eligible for percutaneous coronary intervention (pci). * patient has stable/unstable angina or myocardial infarction (mi): all-comers. * ulmb (medina 1,1,1) with/without left main ostial/shaft lesions. downstream lesions in lad or lcx could be covered by two stents. severe calcification needing rotational atherectomy, orbital atherectomy or laser are included. * diameter stenosis in lad/lm and lcx ≥ 50% by visual estimation or minimal luminal area by ivus in lm ≤6 mm2. exclusion criteria: * restenotic lesions. * patient was allergic to the study stent or protocol-required concomitant medications. * patient is intolerable to dual anti-platelet therapy. * patient has any other serious medical illness that may reduce life expectancy to \<12 months. * patient is a woman who is pregnant or nursing. * patient has a planned procedure that may cause non-compliance with the protocol or confound data interpretation. * patient is participating in another clinical trial. * patients in shock.
expression of cvd and ha between obesity and non-obesity polycystic ovary syndrome (pcos) women in taiwan

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovarian syndrome (pcos) is the most common endocrine disorder in reproductive women. it is estimated that 5 to 10% of women of reproductive age have pcos. one of the major diagnostic criteria of pcos was chronic anovulation which lead to irregular menstruation, amenorrhea, and infertility; the other diagnostic criteria was hyperandrogenism which lead to hirsutism, acne and alopecia. furthermore, pcos is thought as a metabolic disorder, the long-term consequence of pcos were diabetes mellitus and cardiovascular disease, which are potentially dangerous in women health. early diagnosis and prevention is very important to the pcos patients. obesity is the most potential risk of threat to health of populations. there is a major impact of obesity on the pcos related disorders. insulin resistance and distribution of adipose tissue were thought to be the important risk factors of cardiovascular and metabolic syndrome. to treat pcos patients properly,wan-fang hospital had established a specific medical team. we recently published in "fertility and sterility" about the clinical presentation of androgen excess in taiwanese women. hirsutism is much less prevalence (30%) in taiwanese pcos women than that previous reported (65-80%) in thewestern women. it is important to know that some clinical presentation of pcos might have ethic variance. insulin resistance was reported as another candidate that might have ethic variance.we had reported about 40% women in pcos women were obese, it is similar with previous literature reported. obesity is a major factor that could be controlled during the treatment of pcos.weight reduction is one of our methods in pcos treatment. the progressive results for obese pcos women would be facing the risks of diabetes and metabolic syndrome.we thought like to evaluate the benefit of weight reduction program to the prognosis of obese women with pcos. furthermore, it is known that endothelial progenitor cells (epc) be an early marker of cardiovascular disease, we would like to know the role of epc to predict metabolic syndrome in women with pcos. wan-fang hospital has a professional team in pcos treatment and research which including gynecological endocrinologist, cardiologist, medical endocrinologist, specialist in weight reduction. this team had been working well for more that 4 years. we hope we can make a contribution to the study and treatment of pcos in taiwan.


Eligibility criteria:
inclusion criteria: * women who had visited the reproductive endocrinology clinic at taipei medical university - wan fang medical center during april 2004 - march 2007 with the chief complaints of menstrual irregularities, infertility, acne/or hirsutism. exclusion criteria: * women who had been diagnosed with androgen-secreting tumors. * girls who had their menarche less than 3 years prior to the study, or who older than 40. * women with inadequate clinical/biochemical records.

Keywords: obesity, pcos, ha, cvd
a study of exercise endurance and lung hyperinflation in patients with moderate to severe chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe copd. it was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. all patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.


Eligibility criteria:
inclusion criteria: * a diagnosis of stable moderate to severe copd (gold 2006); post-levalbuterol fev1 \>=30% and \< 80% predicted and fev1/fvc\<70% predicted * current or former cigarette smoker * functional residual capacity (frc) measured by body plethysmography \>= 120% of predicted value * baseline dyspnea index (bdi) focal score ≤ 7 at visit 4 exclusion criteria: * history of presence of asthma, allergic rhinitis, or atopy * hospitalization for acute copd exacerbation in the 3 months prior to study entry * respiratory tract infection (including the upper respiratory tract) or copd exacerbation in the 6 weeks prior to study entry * clinically significant respiratory conditions other than copd * chronic use of oxygen therapy \>= 15 hours a day

Keywords: bronchitis, chronic; emphysema
head mounted eye tracking aide for loss of central vision (hetalcev)

Conditions: Age-related Macular Degeneration

Summary: a device has been developed that has eye trackers integrated within the head mounted display (hmd) and can remap text and images around the scotoma in real time to prevent information loss from a central scotoma. it can also carry out other types of image processing such as contrast enhancement and image magnification. the aim of this study is to assess the efficacy of this device on the visual performance of participants suffering from central vision loss, with and without remapping

participants with bilateral central scotomas will be selected for this study during their routine clinical visits at the university of minnesota eye clinic. written consent will be obtained from all participants. each participant will have their scotomas mapped using a nidek mp-1 microperimeter housed in the psychology department to give exact size and shape information. this allows for the extent of each eye's scotoma to be put into the remapping software, and their intersection used in remapping calculation. comparisons will be made between participants with small scotoma, less than 5 degrees, and participants with large scotoma, larger than 5 degrees. experiments to be performed with the device are also divided into two categories. category 1 involves reading of naturalistic text, and everyday task performance. category 2 involves studying the effects of practice with the device on performance in category 1 experiments. participants will schedule an initial one-hour session for testing. during testing, participants will be told about the device and its functionality. main instructions include what patients can expect to experience and see when wearing the hmd. following this, the participants will be instructed on how to wear the hmd. if they have any glasses/ corrective lenses, they can be kept on. once the patients don the hmd, testing will begin. initially, a calibration-free mode will be tested. this will entail asking the subject to focus on a particular point on the screen and checking if the gaze point determined by the eye tracker corresponds to this point. if good calibration is obtained, the investigators proceed with testing. otherwise, a 3-point calibration sequence will be initiated following instructions on the software program. for the 3-point calibration sequence, the participant will be instructed to fixate at 3-5 different points on the screen one at a time. following this calibration sequence, testing will resume and visual performance such as reading speed in words/minute will be measured as the primary outcome measure, with and without remapping.

Eligibility criteria:
inclusion criteria: * 18 years or older * central vision loss from bilateral central scotomas * no cognitive impairment as indicated by a mini-mental state examination (mmse) exclusion criteria: * failed mmse

Keywords: age-related macular degeneration central scotoma head mounted display
venticute in patients with pneumonia or aspiration of gastric contents and intubation/ventilation/oxygenation impairment (by2001/m1-007)

Conditions: Pneumonia

Summary: study to demonstrate that administration of venticute increases survival of patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment.


Eligibility criteria:
main inclusion criteria: * patient has been intubated due to one of the following primary pulmonary insults: aspiration of gastric contents or pneumonia main exclusion criteria: * principal source of infection or sepsis is outside the lung * severe pre-existing lung disease * cancer metastatic to the lung or any end stage malignancy * history of lung, liver, pancreas, small bowel, or bone marrow/stem cell transplantation * patient is morbidly obese * patient has a diagnosis of acute necrotizing pancreatitis additional criteria may apply and examination by an investigator is required to determine eligibility.

Keywords: aspiration of gastric contents